

589230 1.DOC
DES/CD/dcm
November 28, 2005

PATENT APPLICATION
Attorney's Docket No.: 0975.1005-013

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and
Scott Siegel

Application No.: 09/927,703 Group: 1644

Filed: August 10, 2001 Examiner: Phillip Gambel

Confirmation No.: 8249

For: ANTI-TNF ANTIBODIES AND PEPTIDES OF HUMAN TUMOR NECROSIS
FACTOR

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
<u>1/26/2006</u>	<u>Denise Caredeo</u>
Date	Signature
<u>Denise Caredeo</u>	
Typed or printed name of person signing certificate	

STATEMENT UNDER 37 C.F.R. §1.804, §1.806 AND §1.808

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. §1.804, §1.806 and §1.808, the undersigned states as follows:


1. Murine mAb A2 (c134A) was deposited on September 22, 2005, and assigned ATCC Accession Number PTA-7045. The above-referenced application specifically identifies this biological deposit, which was deposited under the Budapest Treaty at the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209. I am a person in position to corroborate that the biological material which was deposited is a biological material

specifically identified in the priority application U.S. Serial No. 07/670,827, filed March 18, 1991 (the filing date of which is relied upon) as filed.

2. Deposit PTA-7045 will be maintained in a public depository for the enforceable life of the patent which issues from the above-referenced application, a term of at least thirty years from the date of deposit or at least five years after the most recent request for the furnishing of a sample of the deposit is received by the depository, whichever is longer.
3. In accordance with 37 C.F.R. §1.808(a)(1), access to deposit PTA-7045 will be available during the pendency of the above-referenced application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122.
4. In accordance with 37 C.F.R. §1.808(a)(2), and except as permitted by 37 C.F.R. §1.808(b), all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent on the above-referenced application.

Respectfully submitted,

By


G. Kevin Townsend

Dated:

4/28/05

Initials: DES/CD/dcm Docket No.: 0975.1005-013 Date: January 26, 2006

This is to acknowledge receipt of the following documents each filed under Certificate of Mailing Procedure 37 C.F.R. 1.8:

☒ Amendment/Reply Fee Letter w/copy
☒ Pet. Ext of Time included in Fee Letter ☐ Sep. Pet Ext Time w/copy
☒ AMENDMENT w/Exhibit A
☐ AMENDMENT AFTER FINAL ACTION
☐ AMENDMENT AFTER ALLOWANCE UNDER 37 CFR § 1.312
☐ REPLY TO OFFICE ACTION
☐ Replacement Sheets [] Sheets ☐ Annotated Sheets [] Sheets
☒ Check for \$ 380.00 ☐ Auth to charge fees
☐ Other Exhibit A and Statement Under 37 C.F.R. § 1.804, § 1.806, and § 1.808

Applicants: Junming Le, *et al*

Application No.: 09/927,703 Filed: August 10, 2001

Title: ANTI-TNF ANTIBODIES AND...

Date received by the PTO:

@PFDesktop\ODMA\MHODMA\HBSR05\iManage\601334\1